Human CCL2/JE/MCP-1 Antibody Summary
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Detection of Recombinant Human CCL2/JE/MCP‑1 by Western Blot. Western blot shows 25 ng of Recombinant Human CCL2/JE/MCP-1 (Catalog # 279-MC), Recombinant Human CCL8/ MCP-2 (Catalog # 281-CP), Recombinant Human CCL7/MCP-3/MARC (Catalog # 282-P3), Recombinant Human CCL13/ MCP-4 (Catalog # 327-P4), Recombinant Human CCL11/Eotaxin (Catalog # 320-EO), Recombinant Mouse CCL2/JE/MCP-1 (Catalog # 479-JE), and Recombinant Rat CCL2/JE/MCP-1 (Catalog # 3144-JE). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CCL2/JE/MCP-1 Monoclonal Antibody (Catalog # MAB279) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for CCL2/JE/ MCP-1 at approximately 11 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.
Chemotaxis Induced by CCL2/JE/MCP‑1 and Neutralization by Human CCL2/JE/MCP‑1 Antibody. Recombinant Human CCL2/JE/ MCP-1 (Catalog # 279-MC) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR2A in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL2/JE/ MCP-1 (0.15 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL2/JE/ MCP-1 Monoclonal Antibody (Catalog # MAB279). The ND50 is typically 0.9-4.5 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL2/JE/MCP-1
CCL2 is a beta -chemokine that is also known as monocyte chemotactic protein 1 (MCP-1). It is produced by a variety of cell types and is chemotactic for monocytes.
Product Datasheets
Citations for Human CCL2/JE/MCP-1 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
28
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration
Authors: Bianca Cioni, Ekaterina Nevedomskaya, Monique H. M. Melis, Johan van Burgsteden, Suzan Stelloo, Emma Hodel et al.
Molecular Oncology
-
The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis
Authors: Teizo Yoshimura, Chunning Li, Yuze Wang, Akihiro Matsukawa
Cellular & Molecular Immunology
-
A patient-designed tissue-engineered model of the infiltrative glioblastoma microenvironment
Authors: R. C. Cornelison, J. X. Yuan, K. M. Tate, A. Petrosky, G. F. Beeghly, M. Bloomfield et al.
npj Precision Oncology
-
The CCL2-CCR2 astrocyte-cancer cell axis in tumor extravasation at the brain
Authors: Cynthia Hajal, Yoojin Shin, Leanne Li, Jean Carlos Serrano, Tyler Jacks, Roger D. Kamm
Science Advances
-
Melatonin Modulates the Microenvironment of Glioblastoma Multiforme by Targeting Sirtuin 1
Authors: SW Lai, YS Liu, DY Lu, CF Tsai
Nutrients, 2019-06-14;11(6):.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma
Authors: Lei Li, Yong-Dong Liu, Yu-Ting Zhan, Ying-Hui Zhu, Yan Li, Dan Xie et al.
Thoracic Cancer
-
Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells
Authors: Mingjing Shen, Yongbing Chen, Lijun Xu, Rongying Zhu, Xiang Xue, Ying Tsai et al.
International Journal of Oncology
-
DL-3-n-butylphthalide protects endothelial cells against advanced glycation end product-induced injury by attenuating oxidative stress and inflammation responses
Authors: Chang-Yun Liu, Zhen-Hua Zhao, Zhi-Ting Chen, Chun-Hui Che, Zhang-Yu Zou, Xiao-Min Wu et al.
Experimental and Therapeutic Medicine
-
Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts
Authors: M Yao, C Smart, Q Hu, N Cheng
Transl Oncol, 2017-07-19;10(5):734-743.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization -
Characterization of Innate Immunity in an Extended Whole Blood Model of Human Islet Allotransplantation
Authors: Maria Hårdstedt, Susanne Lindblom, Alex Karlsson-Parra, Bo Nilsson, Olle Korsgren
Cell Transplantation
-
Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-kappa B Activity
Authors: Paul F Lindholm, Neela Sivapurapu, Borko Jovanovic, André Kajdacsy-Balla
Journal of Clinical and Cellular Immunology
-
CoREST1 promotes tumor formation and tumor stroma interactions in a mouse model of breast cancer.
Authors: Mazumdar, Sohini, Arendt, Lisa M, Phillips, Sarah, Sedic, Maja, Kuperwasser, Charlott, Gill, Grace
PLoS ONE, 2015-03-20;10(3):e0121281.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Secreted ectodomain of sialic acid-binding Ig-like lectin-9 and monocyte chemoattractant protein-1 promote recovery after rat spinal cord injury by altering macrophage polarity.
Authors: Matsubara K, Matsushita Y, Sakai K, Kano F, Kondo M, Noda M, Hashimoto N, Imagama S, Ishiguro N, Suzumura A, Ueda M, Furukawa K, Yamamoto A
J Neurosci, 2015-02-11;35(6):2452-64.
Species: Rat
Sample Types: Whole Cells
Applications: Neutralization -
Macrophages induce differentiation of plasma cells through CXCL10/IP-10.
J. Exp. Med., 2012-09-17;209(10):1813-23.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia
Authors: Kazutoshi Fujita, Charles M. Ewing, Robert H. Getzenberg, J. Kellogg Parsons, William B. Isaacs, Christian P. Pavlovich
The Prostate
-
Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells.
Authors: Dagouassat M, Suffee N, Hlawaty H, Haddad O, Charni F, Laguillier C, Vassy R, Martin L, Schischmanoff PO, Gattegno L, Oudar O, Sutton A, Charnaux N
Int. J. Cancer, 2010-03-01;126(5):1095-108.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Tumour necrosis factor alpha stimulates the production of monocyte chemoattractants by extravillous trophoblast cells via differential activation of MAPK pathways.
Authors: Renaud SJ, Sullivan R, Graham CH
Placenta, 2009-02-08;30(4):313-9.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Pre-eclampsia is associated with dendritic cell recruitment into the uterine decidua.
Authors: Huang SJ, Chen CP, Schatz F, Rahman M, Abrahams VM, Lockwood CJ
J. Pathol., 2008-02-01;214(3):328-36.
Species: Human
Sample Types: Tissue Homogenates, Whole Tissue
Applications: ELISA Development, IHC-Fr -
Eotaxin-2 and colorectal cancer: a potential target for immune therapy.
Authors: Cheadle EJ, Riyad K, Subar D, Rothwell DG, Ashton G, Batha H, Sherlock DJ, Hawkins RE, Gilham DE
Clin. Cancer Res., 2007-10-01;13(19):5719-28.
Species: Human
Sample Types: Tissue Homogenates
Applications: ELISA Development -
Induction of host chemotactic response by Encephalitozoon spp.
Authors: Fischer J, West J, Agochukwu N, Suire C, Hale-Donze H
Infect. Immun., 2006-12-18;75(4):1619-25.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion.
Authors: Abe Y, Fornage M, Yang CY, Bui-Thanh NA, Wise V, Chen HH, Rangaraj G, Ballantyne CM
Atherosclerosis, 2006-10-04;192(1):56-66.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.
Authors: Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P
J. Hepatol., 2006-03-20;44(6):1167-74.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors.
Authors: Penninckx F, Ectors N
Exp. Cell Res., 2005-02-15;303(2):331-42.
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA Development -
The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation.
Authors: Kyriakides TR, Foster MJ, Keeney GE, Tsai A, Giachelli CM, Clark-Lewis I, Rollins BJ, Bornstein P
Am. J. Pathol., 2004-12-01;165(6):2157-66.
Species: Human
Sample Types: Whole Cells
Applications: ICC, Neutralization -
Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells.
Authors: Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, Fitzgerald-Bocarsly P
J. Leukoc. Biol., 2004-01-23;75(3):504-14.
Species: Human
Sample Types:
Applications: Flow Cytometry -
MCP-1 targeting: Shutting off an engine for tumor development
Authors: L Wang, J Lan, J Tang, N Luo
Oncology Letters, 2021-11-19;23(1):26.
-
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Authors: Vergani E, Di Guardo L, Dugo M et al.
Oncotarget
-
Neutrophil microvesicles drive atherosclerosis by delivering miR-155 to atheroprone endothelium
Authors: I Gomez, B Ward, C Souilhol, C Recarti, M Ariaans, J Johnston, A Burnett, M Mahmoud, LA Luong, L West, M Long, S Parry, R Woods, C Hulston, B Benedikter, C Niespolo, R Bazaz, S Francis, E Kiss-Toth, M van Zandvo, A Schober, P Hellewell, PC Evans, V Ridger
Nat Commun, 2020-01-10;11(1):214.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CCL2/JE/MCP-1 Antibody
Average Rating: 4.6 (Based on 5 Reviews)
Have you used Human CCL2/JE/MCP-1 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Used as capture antibody in our NHP ELISA
After biotinylation, used as a capture reagent according to the manufacturer’s protocol (Meso Scale Diagnostics LLC).
Paired with SulfoTag-modified AF-279-NA as a detection antibody. Calibration curves with Recombinant Human CCL2 (279-MC-010/CF) is shown (dynamic range 6-25,000 pg/ml)